Abstract:Surgical intervention for stage IV non-small cell lung cancer (NSCLC) is still controversial. This study sought to evaluate the clinical effects of surgical intervention on survival in patients with stage IV NSCLCs and to identify the cohort benefitting the most from surgery.A retrospective study from the Surveillance, Epidemiology, and End Results database was performed to compare the survival of stage IV NSCLC patients who had undergone surgery with those who did not undergo surgery. Overall survival (OS) was evaluated using the Kaplan-Meier method and the log-rank test. The Cox proportional hazards model was used for multivariate analysis.The total number of eligible patients was 43,538, including 16.8% in the M1a stage and 83.2% in the M1b stage. The percentages of patients with no surgery (NONE), only metastatic tumor resection (MTR), only primary tumor resection (PTR), and both primary and metastatic tumor resection (PMTR) were 89.0%, 6.7%, 3.5%, and 0.8%, respectively; the corresponding 5-year survival rates were 2.0%, 4.0%, 13.0%, and 20.0%, respectively (P < 0.001); and the corresponding OS rates were 11.1 months, 14.7 months, 29.4 months, and 34.9 months, respectively (P < 0.001). Notably, the pairwise comparisons of 5-year survival rate and OS among the subgroups were all statistically significant. The multivariate analysis showed that surgical intervention was correlated with longer survival in patients with stage IV NSCLC. The stratified analysis showed significant differences in the OS on strata of the M1a stage and strata of the M1b stage. In the M1a stage, patients with PTR had significantly better OS than those with NONE (P < 0.001) or MTR (P < 0.001) but showed no significant differences compared with those with PMTR (P = 0.174); patients with MTR did not have prolonged survival compared with patients with NONE (P = 0.185), and they also did not have prolonged survival compared with patients with PMTR (P = 0.052). In the M1b stage, pairwise comparisons of OS were all statistically significant among the subgroups (P < 0.001).Surgical intervention can prolong survival to different degrees according to the modalities of surgery in stage IV NSCLC.

The Benefit of Surgery During Systematic Therapy for Gastrointestinal Stromal Tumor Liver Metastasis: a SEER-based Retrospective Study

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Impact of Surgical Resection for Gastrointestinal Stromal Tumor (GIST) Patients with Initially Diagnosed Synchronous Hepatic Metastases on Long-Term Survival Outcomes

Role of Surgery in the Management of Liver Metastases from Gastrointestinal Stromal Tumors

Effects of surgical management for gastrointestinal stromal tumor patients with liver metastasis on survival outcomes

Liver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center.

Surgery Prolongs the Survival of Patients with Metastatic, Recurrent, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Response to Imatinib Mesylate Treatment: A Systematic Review and Meta-analysis

[Efficacy analysis of targeted therapy combined with surgery in the treatment of recurrent and metastatic gastrointestinal stromal tumor].

Surgery plus TKIs therapy for gastrointestinal stromal tumors

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

Clinical analysis of targeted chemotherapy combined with surgical resection in locally advanced and recurrent/metastatic gastrointestinal stromal tumor

[Efficacy of Tyrosine Kinase Inhibitor Therapy Combined with Surgical Resection in Patients with Metastatic Gastrointestinal Stromal Tumor].

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.

Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib

[Surgical Treatment for Patients with Advanced Gastrointestinal Stromal Tumor after Targeted Therapy].

Advanced Gastrointestinal Stromal Tumor Patients Benefit from Palliative Surgery after Tyrosine Kinase Inhibitors Therapy

Cytoreductive Surgery Offers Prognostic Benefits in Metastatic Gastrointestinal Stromal Tumors with Generalized Progression Following Imatinib Therapy: a Single Institute Retrospective Study

The Role of Surgical Resection Following Tyrosine Kinase Inhibitors Treatment in Patients with Advanced Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis.

[Surgical Treatment for Gastrointestinal Stromal Tumor].

The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study

Surgical Resection for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: a Protocol for a Systematic Review and Meta-Analysis Update